Search the site

Honorary Research Associate

Clinical Associate Professor Deborah Lehmann

Honorary Emeritus Fellow

Cardiac monitoring safety assessment framework for early phase group a streptococcal vaccine trials

This paper presents a comprehensive cardiac safety framework for early clinical development of Streptococcus pyogenes (Group A Streptococcus) vaccines, endorsed by the Strep A Vaccine Global Consortium and the Australian Strep A Vaccine Initiative. Given historical concerns about vaccine-associated acute rheumatic fever, we have established standardized echocardiography protocols integrated with clinical assessment for monitoring cardiac safety in early-phase vaccine trials.

Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201

Our international team highlights issues with efficacy reports in several studies on DMG with the new drug ONC201.

Vaccine Trials Group

We are evaluating new vaccines for a range of diseases including influenza, pneumococcal, meningococcal and common infections such as otitis media (glue ear).

Clinical significance and applications of oscillometry

Recently, "Technical standards for respiratory oscillometry" was published, which reviewed the physiological basis of oscillometric measures and detailed the technical factors related to equipment and test performance, quality assurance and reporting of results. Here we present a review of the clinical significance and applications of oscillometry.

Calcium and Vitamin D for obesity: review of randomized controlled trials

Obesity often coexists with low calcium intake and vitamin D insufficiency.

An introduction to clinical trial design

This manuscript will give a brief overview of clinical trial design including the strengths and limitations of various approaches

Seed grant preps world-first ear infection prevention therapy for human trials

The Kids Research Institute Australia has secured a State Government grant to prepare a nasal therapy designed to prevent childhood ear infections for a world-first clinical trial.

Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

The IHSG recommends that the frequency of detection of a glucose concentration <3.0mmol/L, to be included in clinical trial reports of glucose lowering drugs.